TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20869038

Group type: EXPERIMENTAL
Intervention: 17‐alpha‐hydroxyprogesterone (17P)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 18982439

Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (n-3 PUFAs)
Number of subjects: 44
Study: 17091128

Group type: EXPERIMENTAL
Intervention: Naltrexone (12 mg) + THC (20 mg)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Naltrexone (12 mg) + THC (40 mg)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Naltrexone (12 mg) + THC (2.5 mg)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Naltrexone (12 mg) + THC (10 mg)
Number of subjects: 43
Study: 15491089

Group type: EXPERIMENTAL
Intervention: Galloy (gallium based)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Aristaloy (amalgam based)
Number of subjects: 90
Study: 11485281

Group type: EXPERIMENTAL
Intervention: Atropa belladonna tincture (ABT) 5 ml
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Atropa belladonna tincture (ABT) 1 ml
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Atropa belladonna tincture (ABT) 2 ml
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 9771953

Group type: EXPERIMENTAL
Intervention: Cisplatin at a dose of 80 mg/m2 on day 1 and etoposide at a dose of 100 mg/m2 on days 1, 2 and 3
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 42
Study: 8143394

Group type: EXPERIMENTAL
Intervention: 0.3% ofloxacin
Number of subjects: 160

Group type: COMPARATOR
Intervention: 0.3% tobramycin
Number of subjects: 160
Study: 3633356

Group type: EXPERIMENTAL
Intervention: School nursing follow-up services
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Telephone follow-up
Number of subjects: 287
Study: 29495741

Group type: EXPERIMENTAL
Intervention: Single-formant interferers (created using the time-reversed F2 frequency contour, RMS-matched to F2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interferers comprising either one formant (F1) or all three formants (F1, F2, F3)
Number of subjects: 0
Study: 29901373

Group type: EXPERIMENTAL
Intervention: Chitosan dressing
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard dressing
Number of subjects: 20
Study: 25134034

Group type: EXPERIMENTAL
Intervention: Brief alcohol use disorder treatments
Number of subjects: 89

Group type: COMPARATOR
Intervention: Change on their own (control group)
Number of subjects: 89
Study: 22538671

Group type: EXPERIMENTAL
Intervention: Suction drain positioned in the subhepatic space
Number of subjects: 106

Group type: COMPARATOR
Intervention: Sham drain
Number of subjects: 106
Study: 20085614

Group type: EXPERIMENTAL
Intervention: Feldspathic ceramic
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: IPS Empress II
Number of subjects: 30

Group type: COMPARATOR
Intervention: Gradia (laboratory composite)
Number of subjects: 30
Study: 17714844

Group type: EXPERIMENTAL
Intervention: 20 mg D‐amphetamine alone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 100 mg riluzole alone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: d‐amphetamine plus riluzole
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 18634926

Group type: EXPERIMENTAL
Intervention: Formocresol (FC)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ferric sulphate (FS)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Calcium hydroxide (Ca(OH)(2))
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Mineral trioxide aggregate (MTA)
Number of subjects: 16
Study: 15010405

Group type: EXPERIMENTAL
Intervention: 3.5% urea-linked gelatin (GEL group)
Number of subjects: 110

Group type: COMPARATOR
Intervention: 6% hydroxyethyl starch 200/0.5 (HES group)
Number of subjects: 110
Study: 10909945

Group type: EXPERIMENTAL
Intervention: Audio computer-assisted self-interviewing (ACASI)
Number of subjects: 2877
Study: 9049574

Group type: EXPERIMENTAL
Intervention: Gradual withdrawal from benzodiazepines
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 8449579

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil 125 mg twice daily for three days
Number of subjects: 163

Group type: COMPARATOR
Intervention: Ofloxacin 100 mg twice daily for three days
Number of subjects: 163
Study: 2937337

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 200

Group type: COMPARATOR
Intervention: Diazemuls
Number of subjects: 200
Study: 31967673

Group type: EXPERIMENTAL
Intervention: Bevacizumab (8 mg/kg) and Everolimus (4 mg/m2)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Bevacizumab (10 mg/kg) and Everolimus (4 mg/m2)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Bevacizumab and Everolimus
Number of subjects: 15
Study: 30657852

Group type: EXPERIMENTAL
Intervention: 9 weeks trastuzumab
Number of subjects: 866

Group type: EXPERIMENTAL
Intervention: 1 year trastuzumab
Number of subjects: 866

Group type: COMPARATOR
Intervention: TILs <20%
Number of subjects: 866

Group type: COMPARATOR
Intervention: TILs ≥20%
Number of subjects: 866

Group type: COMPARATOR
Intervention: Comparison of short vs long arm for TILs <20%
Number of subjects: 866

Group type: COMPARATOR
Intervention: Comparison of short vs long arm for TILs ≥20%
Number of subjects: 866
Study: 28081369

Group type: EXPERIMENTAL
Intervention: Ethanol cookstove intervention
Number of subjects: 324

Group type: COMPARATOR
Intervention: Control (kerosene or firewood)
Number of subjects: 324

Group type: COMPARATOR
Intervention: Control (kerosene)
Number of subjects: 324
Study: 25842470

Group type: EXPERIMENTAL
Intervention: Cosmetic topical slimming treatment
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 23976883

Group type: EXPERIMENTAL
Intervention: Sodium dichloroisocyanurate (NaDCC) tablets distributed during bi-monthly household visits; intervention included an intensive promotion campaign.
Number of subjects: 2986

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 2986

Group type: EXPERIMENTAL
Intervention: Sodium dichloroisocyanurate (NaDCC) tablets intervention.
Number of subjects: 2986
Study: 21896611

Group type: EXPERIMENTAL
Intervention: Adenoidectomy
Number of subjects: 111

Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 111
Study: 19011582

Group type: EXPERIMENTAL
Intervention: Continuous passive motion (CPM) treatment for 1 hour once a day for 20 days over 4 weeks
Number of subjects: 57

Group type: COMPARATOR
Intervention: Conventional physiotherapy treatment (CPT) protocol for 1 hour once a day for 20 days over 4 weeks
Number of subjects: 57
Study: 16918854

Group type: EXPERIMENTAL
Intervention: Intervention designed to help families manage a child's asthma
Number of subjects: 3408
Study: 15536845

Group type: EXPERIMENTAL
Intervention: Argon laser curing (10 seconds, 250 mW)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conventional visible light curing (40 seconds)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 45
Study: 11747981

Group type: EXPERIMENTAL
Intervention: Metyrapone (1 g orally daily for 14 days)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31

Group type: COMPARATOR
Intervention: Metyrapone and Placebo
Number of subjects: 31
Study: 9034837

Group type: EXPERIMENTAL
Intervention: HELP
Number of subjects: 40

Group type: COMPARATOR
Intervention: Hemodilution therapy
Number of subjects: 40
Study: 8323420

Group type: EXPERIMENTAL
Intervention: Physician prompting with diagnostic information and counseling directives
Number of subjects: 214

Group type: COMPARATOR
Intervention: No physician prompting (control group)
Number of subjects: 214
Study: 3084332

Group type: EXPERIMENTAL
Intervention: Ambulatory continuous enteral nutrition (CEN) at a rate of 35-45 kcal/kg/d (lipids: 35%, carbohydrates: 45%)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Conventional non-ambulatory CEN
Number of subjects: 98
Study: 31394939

Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field therapy (PEMF) for 12 weeks
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field therapy (PEMF) during exercise
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field therapy (PEMF) in subjects with resting hypertension (n=11)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field therapy (PEMF) in subjects with resting hypertension
Number of subjects: 44

Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 44
Study: 30181075

Group type: EXPERIMENTAL
Intervention: Usual care + phone call 48 hours after discharge
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Usual care + text message 48 hours after discharge
Number of subjects: 251

Group type: COMPARATOR
Intervention: Control group (usual discharge)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 251
Study: 27531316

Group type: EXPERIMENTAL
Intervention: Mean time goals for 5 Fundamentals of Laparoscopic Surgery (FLS) tasks
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Best time goals for 5 Fundamentals of Laparoscopic Surgery (FLS) tasks
Number of subjects: 62

Group type: COMPARATOR
Intervention: No time goals for 5 Fundamentals of Laparoscopic Surgery (FLS) tasks
Number of subjects: 62
Study: 25308211

Group type: EXPERIMENTAL
Intervention: Theracurmin (180 mg/day)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Theracurmin
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 22309202

Group type: EXPERIMENTAL
Intervention: Low Level of Response-based (LRB) Group
Number of subjects: 64

Group type: COMPARATOR
Intervention: State-of-the-Art (SOTA) Group
Number of subjects: 64
Study: 20383874

Group type: EXPERIMENTAL
Intervention: High-dose NAC (1200 mg) plus saline hydration (Group 1, n=25)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Saline hydration (Group 2, n=20)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Comparison of both groups
Number of subjects: 45
Study: 18757783

Group type: EXPERIMENTAL
Intervention: Odiparcil with aspirin (ASA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Odiparcil with enoxaparin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 15502972

Group type: EXPERIMENTAL
Intervention: D-cycloserine 50 mg/day
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 11916799

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.125% with fentanyl 2 microg/mL at 10 mL/h
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.0625% with fentanyl 2 microg/mL at 10 mL/h
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.04% with epinephrine 1:600,000 and fentanyl 2 microg/mL at 10 mL/h
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 0
Study: 9583771

Group type: EXPERIMENTAL
Intervention: Amantadine (200 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 8559197

Group type: EXPERIMENTAL
Intervention: eberconazole cream 1% once daily (group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: eberconazole cream 1% twice daily (group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: eberconazole cream 2% once daily (group C)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: eberconazole cream 2% twice daily (group D)
Number of subjects: 60
Study: 2507630

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 830880

Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 35

Group type: COMPARATOR
Intervention: Lactose placebo (Control)
Number of subjects: 35
Study: 31590688

Group type: EXPERIMENTAL
Intervention: Web-based family health history collection tool and decision support platform (MeTree)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-list control (access to MeTree 12 months post-consent)
Number of subjects: 0
Study: 28301292

Group type: EXPERIMENTAL
Intervention: Pulse width modulated (PWM) red LED light (625 nm, 76 Hz, 23% Duty Cycle) applied for 2 minutes during surgery
Number of subjects: 263

Group type: COMPARATOR
Intervention: Control group (no PWM red LED light treatment)
Number of subjects: 263
Study: 25062900

Group type: EXPERIMENTAL
Intervention: Multimodal physical training for 16 weeks
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 45
Study: 23579103

Group type: EXPERIMENTAL
Intervention: Ropivacaine 7.5mg/mL
Number of subjects: 102

Group type: COMPARATOR
Intervention: Lidocaine 10mg/mL
Number of subjects: 102
Study: 21994354

Group type: COMPARATOR
Intervention: ACE527 (three-strain combination live attenuated vaccine) at doses of 10^10 and 10^11 total CFU
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19523014

Group type: COMPARATOR
Intervention: i.v. omeprazole (OME group, 40 mg i.v. infusion every 12 h for 3 days)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: oral rabeprazole (RAB group, 20 mg twice daily for 3 days)
Number of subjects: 156

Group type: COMPARATOR
Intervention: i.v. omeprazole (OME group)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: oral rabeprazole (RAB group)
Number of subjects: 156
Study: 16766333

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate 0.05% shampoo
Number of subjects: 162

Group type: COMPARATOR
Intervention: Tar blend 1% shampoo
Number of subjects: 162
Study: 23570221

Group type: EXPERIMENTAL
Intervention: VitalPoll Telemedicine System (VTS)
Number of subjects: 0
Study: 11688083

Group type: EXPERIMENTAL
Intervention: Level 1 sugar (10 mg of iron/kg of sugar)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Level 2 sugar (100 mg of iron/kg of sugar)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Both groups (considering only anemic children)
Number of subjects: 93
Study: 9716763

Group type: EXPERIMENTAL
Intervention: Five weekly practice sessions (Group A)
Number of subjects: 12

Group type: COMPARATOR
Intervention: No practice (Group B)
Number of subjects: 12
Study: 8288056

Group type: EXPERIMENTAL
Intervention: Intensified Conventional Treatment (ICT)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Standard Treatment (ST)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 102
Study: 2605074

Group type: EXPERIMENTAL
Intervention: Halothane (1 MAC end‐tidal concentration)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Propofol infusion (control group)
Number of subjects: 16
Study: 4394650

Group type: EXPERIMENTAL
Intervention: Intravenous propranolol administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral propranolol administration
Number of subjects: 0
Study: 31034700

Group type: EXPERIMENTAL
Intervention: Topical glaucoma medications
Number of subjects: 12899

Group type: EXPERIMENTAL
Intervention: Patient-related factors (gender, socioeconomic status, language spoken at home, lifestyle and comorbidities) and drug-related factors (total number and drug class)
Number of subjects: 12899

Group type: EXPERIMENTAL
Intervention: Living in remote areas
Number of subjects: 12899

Group type: EXPERIMENTAL
Intervention: Family income over 70,000 AUD/year
Number of subjects: 12899

Group type: EXPERIMENTAL
Intervention: Speaking other languages at home
Number of subjects: 12899

Group type: EXPERIMENTAL
Intervention: Using cholinergic classes of medications
Number of subjects: 12899
Study: 30922017

Group type: EXPERIMENTAL
Intervention: Self-heating blanket (SHB)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Forced-air blanket (FAB)
Number of subjects: 86
Study: 25618418

Group type: EXPERIMENTAL
Intervention: Wholegrain diet (>80 g/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Refined grain diet (<16 g/day)
Number of subjects: 0
Study: 25209550

Group type: EXPERIMENTAL
Intervention: HAART initiation
Number of subjects: 400
Study: 22176653

Group type: EXPERIMENTAL
Intervention: High-dose ascorbic acid (vitamin C) for 4 weeks
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 53
Study: 20078871

Group type: EXPERIMENTAL
Intervention: ACTH
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Vigabatrin
Number of subjects: 56
Study: 17071939

Group type: EXPERIMENTAL
Intervention: Topotecan 0.75 mg/m2, days 1-5, and carboplatin AUC 5, day 5 (arm A)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Topotecan 1.25 mg/m2, days 1-3, and carboplatin AUC 5, day 3 (arm B)
Number of subjects: 100
Study: 16291354

Group type: EXPERIMENTAL
Intervention: Iron and zinc supplementation (30 mg ferrous fumarate, 30 mg zinc oxide, both, or placebo daily for 6 months)
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 602

Group type: COMPARATOR
Intervention: Teacher ratings
Number of subjects: 602
Study: 11835297

Group type: EXPERIMENTAL
Intervention: Very low calorie diet (VLCD) program
Number of subjects: 128
Study: 10404573

Group type: EXPERIMENTAL
Intervention: Recurrent low back pain group (n = 40)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Disc degeneration at 15 years
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Disc protrusion and Scheuermann-type changes at 15 years
Number of subjects: 80

Group type: COMPARATOR
Intervention: Asymptomatic control group (n = 40)
Number of subjects: 80
Study: 8681312

Group type: EXPERIMENTAL
Intervention: 0.5 micrograms/kg rHCNTF
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: 1 microgram/kg rHCNTF
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: 3 micrograms/kg rHCNTF
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: 7 micrograms/kg rHCNTF
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: 10 micrograms/kg rHCNTF
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: 30 micrograms/kg rHCNTF
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 2188023

Group type: EXPERIMENTAL
Intervention: Educational curriculum focused on child development, family support, and pediatric follow-up
Number of subjects: 985

Group type: COMPARATOR
Intervention: Only pediatric follow-up
Number of subjects: 985
Study: 6997792

Group type: EXPERIMENTAL
Intervention: Mefenamic acid
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 6862582

Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (50 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg) in hyperadrenergic patients
Number of subjects: 12
Study: 31082512

Group type: COMPARATOR
Intervention: Standardised Chinese herbal medicine (CHM)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Individualised Chinese herbal medicine (CHM)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 30026335

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5 mg
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 813

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 813
Study: 26837479

Group type: EXPERIMENTAL
Intervention: Angioplasty
Number of subjects: 118

Group type: COMPARATOR
Intervention: Supervised exercise therapy
Number of subjects: 118
Study: 24759256

Group type: EXPERIMENTAL
Intervention: Grains of paradise (GP) extract (30 mg/d) for 4 weeks
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 23038982

Group type: EXPERIMENTAL
Intervention: Aqueous extract of dried barberry (600 mg daily for 4 weeks)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 20807094

Group type: EXPERIMENTAL
Intervention: ACVBP
Number of subjects: 652

Group type: COMPARATOR
Intervention: ECVBP
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: ACVBP (in patients with DLBCL)
Number of subjects: 652
Study: 17984165

Group type: EXPERIMENTAL
Intervention: torcetrapib plus atorvastatin
Number of subjects: 15067

Group type: COMPARATOR
Intervention: atorvastatin alone
Number of subjects: 15067
Study: 15845130

Group type: EXPERIMENTAL
Intervention: Standard assessments at age 3
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Rate of non-verbal communicative acts from interactive play-based assessment at age 2
Number of subjects: 26

Group type: COMPARATOR
Intervention: Standard assessments at age 2
Number of subjects: 26
Study: 12456431

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 10495176

Group type: EXPERIMENTAL
Intervention: Water irrigation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline irrigation
Number of subjects: 20
Study: 8543208

Group type: EXPERIMENTAL
Intervention: Pulse-synchronised image acquisition using an electrocardiographic signal
Number of subjects: 25

Group type: COMPARATOR
Intervention: Normal image acquisition
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Pulse-synchronised image acquisition
Number of subjects: 25
Study: 1961959

Group type: COMPARATOR
Intervention: Thiopental, 4 mg/kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Propofol, 2.5 mg/kg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Thiopental with N2O at 66%
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Thiopental
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 7026795

Group type: EXPERIMENTAL
Intervention: Training in muscle relaxation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Information about sensations experienced during surgery
Number of subjects: 0
Study: 31737175

Group type: EXPERIMENTAL
Intervention: Silybin with vitamin D and vitamin E (RealSIL 100D®) for six months
Number of subjects: 90

Group type: COMPARATOR
Intervention: Not treated (control group)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Silybin with vitamin D and vitamin E (RealSIL 100D®) for six months in patients with concomitant metabolic syndrome
Number of subjects: 90
Study: 27911295

Group type: EXPERIMENTAL
Intervention: Plasma Exchange (PE) with 5% albumin (Albutein®, Grifols)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (sham)
Number of subjects: 42